News Articles for Argent BioPharma

MGC Pharmaceuticals have executed another major new medical marijuana deal, this time with a European medicinal cannabis product manufacturer and distributor that has signed on for annual sales worth at least $1m. New customer Mabsut Life says the deal is just the first in a series of agreements it expects with MGC Pharmaceuticals under a strategic partnership.

MGC Pharmaceuticals have signed a distribution deal with local pharmaceutical distributor HL Pharma to launch its cannabis-based epilepsy treatment, CannEpil, in Australia. MGC wants to target the more than 70,000 Australian sufferers of the condition and sees it as a significant additional revenue stream ahead. The company says it now has a pathway to deliver the drug to patients from 2018.

Whilst most other medical marijuana companies are still trying to work out how to make money, ASX-listed MGC Pharmaceuticals are busy collecting purchase orders for their cannabis based products. The company has signed a binding heads of agreement with local pharmaceutical distributor, HL Pharma to distribute MGC's low cost, cannabis based epilepsy drug CannEpil in Australia.

ASX-listed MGC Pharmaceuticals has signed the first of three sale agreements with Korean cosmetics manufacturer Varm Cosmo as part of the Perth-listed company's $40 million deal with the Asian skincare business. MGC says the initial $8 million order will be followed by two more orders in the coming weeks to complete the landmark cannabis supply agreement.

MGC Pharmaceuticals has hit a new high with expected monthly sales soaring to $3m from a $40m deal to supply its white labelled cannabis based cosmetic products to Korean cosmetics manufacturer, Varm Cosmo. The agreement is set to transform MGC Pharmaceuticals, Australia's leading listed medical cannabis company with its products supplied in bulk to Varm Cosmo.

Medical cannabis company MGC Pharmaceuticals has locked in a supply agreement that it expects to net about $20 million in annual revenue.

ASX-listed MGC Pharmaceuticals have harvested over 4,000 kilograms of cannabis for use in their range of marijuana-derived products as the Perth-listed company progresses its promising growing operations in Europe. MGC's botanical division, largely based in the EU, is also on the verge of harvesting more than 450 medicinal cannabis plants for use in their genetic research program.

MGC Pharmaceuticals have strengthened their position as a market leader in the booming medical marijuana market, securing a distribution deal for their products in Central and Eastern Europe. The exclusive agreement was signed with leading pharmaceutical distribution company, Lenis and will see the Perth-listed company's cannabis-derived products made available in more than 15 countries in the region.

ASX-listed MGC Pharmaceuticals has bolstered its European medicinal cannabis growing operations by shifting nearly 500 marijuana plants to the company's facilities in the Czech Republic. MGC is moving full steam ahead with its botanical division, largely based in the EU, after last month receiving a full European licence to grow cannabis.

MGC Pharmaceuticals has signed a distribution deal to supply its medicainal marijuana products across Slovenia, Croatia and Bosnia. The exclusive agreement with leading Slovenian laboratory supplier, Mikro+Polo, builds on positive momentum at MGC after it was given a full European licence to grow and cultivate cannabis this month.

MGC Pharmaceuticals will breed and register new medicinal cannabis strains in Europe under a research partnership with Solvenia's leading university. The new agreement with the University of Ljubljana adds to an impressive bank of medicinal Cannabis research activity by MGC and gives the ASX-listed company a potential inside track to the European market.

An independent clinical trial of MGC Pharma's cannabis-based dermatological creams has produced spectacular results with the trials showing an 80% improvement in acne prone skin, 73% improvement in psoriatic plaques, 86% improvement of irritated skin and over 70% improvement in the visual appearance of redness, dryness, flaky and oily skin conditions.

Roby Zomer, founder of MGC Pharmaceuticals, has been appointed chief executive officer. Mr Zomer was its executive director and chief technical officer prior to this appointment.

MGC Pharmaceuticals has cemented its position in the Australian medical marijuana market, signing a major research agreement with the Royal Melbourne Institute of Technology. The deal will see MGC and RMIT collaborate on medical cannabis research initiatives targeted at a range of diseases including cancer and establish an “International Library of Cannabis Medicine”.

Medicinal marijuana player MGC Pharmaceuticals are on a mission to be one of the first ASX listed companies to garner serious revenues from medicinal cannabis derived products. The company announced this week they had signed up wholesalers in Europe to market their cannabis derived skin care and cosmetics lines.

Whilst many other medical marijuana hopefuls are still talking up their opportunities in the industry, Perth listed MGC Pharmaceuticals have produced their first cannabinoid extracts at the company's brand new European extraction facility. The milestone means MGC remains on track for commercial production to commence in the third quarter of this year.

Medicinal cannabis player MGC Pharmaceuticals remains on schedule for its first commercial production of medical marijuana, with the Perth-based company's European cannabis extraction facility completing construction. MGC expects the initial commercial cannabinoid extraction to commence in Q3.

Medicinal cannabis player MGC Pharma has easily raised $10 million as it looks to fast-track acquisitions and accelerate development of its cannabis-derived products. MGC will use the funds to ramp up its medical R&D program and expand sales of its cosmetics and dermatological cannabis-derived lines with the latter to fund the former.

ASX-listed MGC Pharmaceuticals' cannabis-derived medicinal products will be fast-tracked to Australia following federal government changes to national medical marijuana laws. The changes mean patients that are prescribed medicinal cannabis will be able to import their medication from local providers such as MGC Pharmacueticals.

ASX-listed MGC Pharmaceuticals are on schedule to complete a major commercial and operational milestone, with their medical grade cannabis extraction facility nearing completion in Slovenia. The new facility will allow the Perth-based company to ramp up its production of cannabis derivative cannabidiol to 3,000kg per year.

In a bold move, ASX-listed MGC Pharmaceuticals has announced it will undertake a new clinical trial to detremine how medicinal cannabis could potentially treat young epilepsy sufferers. The Perth-based company believes the study could present a significant commercial opportunity in the medical marijuana space and it may add a third revenue stream for the company.

ASX-listed MGC Pharmaceuticals has completed the acquisition of Czech-based medical cannabis company Panax Pharma. The deal will boost MGC's research capabilities by giving the company access to leading growing and research facilities in the Czech Republic. MGC said it had settled on a binding heads of agreement to acquire up to 100 per cent equity in Panax.

ASX-listed MGC Pharmaceuticals march towards full commercialisation of its cannabis-based dermatological skin care line is a step closer with the company announcing the start of human clinical trials of its products. The company says it plans to commence sales of its unique derma skin care range that will target acne amongst other things from September.

Medical marijuana company MGC Pharma has been given the tick of approval to sell its brand new cannabis-based dermatological skincare range in the European Union. MGC sees the green light from the European Cosmetics Products Notifications Portal as a major step forward for its new skin care range that will treat acne, psoriasis and seborrhoea.

ASX-listed MGC Pharmaceuticals says it is on schedule to commence production of research grade cannabis by mid-2017 after harvesting its first crop at its Slovenian facilities. In a strong finish to 2016, the company has also confirmed the execution of its deal to acquire Czech-based medical cannabis company Panax Pharma on more favourable terms.

In a move that is likely to ramp up its production and research capabilities, MGC Pharmaceuticals has signed a new, renegotiated, binding heads of agreement to acquire Czech-based medical cannabis company Panax Pharma. Under the deal, the Perth-based company will gain access to world-leading facilities in the Czech Republic for its medical cannabis research.

Whilst most medical Marijuana companies are still trying to work out how to monetize their businesses, MGC Pharmaceuticals are busy locking down international distribution deals with real revenue flows for their unique, Cannabis based skin care line, MGC Derma. The company announced last week it had secured its first major sales order worth around AUD$65,000.

ASX-listed MGC Pharma is a step closer to breaking into the lucrative European skincare market, with the medical cannabis company commencing official EU registration for its cannabis-based cosmetics used to treat conditions such as acne, psoriasis and seborrhoea.

MGC Pharmaceuticals says delivery of its Californian distribution deal for its cannabis-based skincare products is imminent. In an operations update, the medical cannabis hopeful says it is ramping up cosmetics production at its Slovenian facility and is in advanced discussions on additional distribution agreements as it ramps up its international presence.

MGC Pharma and The University of Sydney have released a new report on the clinically proven benefits of medicinal cannabis in a bid to increase its acceptance and draw attention to its potential medical benefits. More than 100 studies are currently underway which will provide a base load of clinical evidence for doctors and patients.

MGC Pharma has moved a step closer to conducting clinical trials of medical cannabis in Australia and Europe after signing a deal to partner with Epilepsy Action Australia. The agreement means MGC will collaborate with Australia's leading epilepsy association on future trials into how medical cannabis can treat the debilitating condition.

MGC Pharmaceuticals has taken the next step towards launching its potentially breakthrough range of cannabis based skincare products next year after Recent microbiology testing in Slovenia showed “no adverse reactions” to MGC cannabis products that treat psoriasis, acne and seborrhoea ailments. The company says it is on track for a full skin care line roll out in 2017.

Medical cannabis company MGC Pharmaceuticals has agreed to sell two African-based exploration permits and related data for $500,000 in cash. The legacy mining assets no longer form part of the company's core business focus as it finalises the transition away from mineral exploration as Erin Resources and into a leading edge medical marijuana company.

MGC Pharmaceuticals have done what few other medical cannabis companies have managed to do – make money.The company received first revenues from its “MGC Derma” medical cannabis based line of anti-ageing cosmetics this week from their Californian distributor who has committed to buy 1.2m Euro's worth of product in the first year.

Perth based MGC Pharmaceuticals have planted their first medical cannabis crop at their licensed growing facility in Slovenia. The company's first crop will be around 5000 square meters in area and will be used to evaluate the best soil, nutrients and growing conditions for the planting of future large scale crops. The harvest will be used for cosmetic and medicinal purposes.

The dominos are starting to fall for ASX listed Medical Cannabis upstart MGC Pharma, with its third regulatory approval in 3 months being granted. The company will now have the right to market its unique medical cannabis based cosmetic line known as “MGC Derma” into the $1.9b a year Canadian market after the Canadian regulatory authority, Health Canada approved the product.

MGC Pharma have broken into the $11b American skin care market after achieving US Food and Drug Administration approval for their “MGC Derma” cosmetics line manufactured from medical cannabis. They recently secured the notoriously hard to get FDA approval giving them the right to market their products into all US states and they have already secured a 1.2m Euro order.

Israel-based materials company Dotz Nano has joined the wave of tech firms from that country seeking to raise capital in Australia via a listing on the ASX.

The European Commission's Cosmetic Products Notification Portal has approved ASX listed MGC Pharma's unique cannabis based skin care and cosmetic line to be sold in Europe. The approval marks a major milestone in the company's strategy to distribute its MGC Derma Cannabidiol based cosmetic products throughout Europe via its partner network and online portal.

Medical cannabis hopeful MGC Pharmaceuticals has upped its capital raising to $5 million after its initial $3.5 million raising closed oversubscribed.